Nasopharyngitis (Common Cold) – Pipeline Review, H2 2012

Published by: Global Markets Direct

Published: Jul. 31, 2012 - 35 Pages

Table of Contents

Introduction

Global Markets Direct Report Coverage

Nasopharyngitis (Common Cold) Overview

Therapeutics Development

An Overview of Pipeline Products for Nasopharyngitis (Common Cold)

Nasopharyngitis (Common Cold) Therapeutics under Development by Companies

Nasopharyngitis (Common Cold) Therapeutics under Investigation by Universities/Institutes

Late Stage Products

Comparative Analysis

Early Clinical Stage Products

Comparative Analysis

Pre-Clinical Stage Products

Comparative Analysis

Nasopharyngitis (Common Cold) Therapeutics – Products under Development by Companies

Nasopharyngitis (Common Cold) Therapeutics – Products under Investigation by Universities/Institutes

Companies Involved in Nasopharyngitis (Common Cold) Therapeutics Development

Hydra Biosciences, Inc.

Nasopharyngitis (Common Cold) – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Resfenol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Smart Textiles - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Camphor + Cineol + Menthol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TRPM8 Antagonist - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Nasopharyngitis (Common Cold) Therapeutics – Discontinued Products

Nasopharyngitis (Common Cold) Therapeutics - Dormant Products

Nasopharyngitis (Common Cold) – Product Development Milestones

Featured News & Press Releases

Aug 26, 2011: Afexa Completes Interim Analysis On COLD-FX Pediatric Multi-Centre Clinical Trial

Oct 21, 2010: Afexa Launches Multi-Center Pediatric Clinical Trial On Cold/Flu Remedy Cold-FX

Dec 28, 2007: Perrigo Announces FDA Approval For Over The Counter Cetirizine Hydrochloride Tablets

Dec 20, 2002: Wyeth Consumer Healthcare Receives Final Approval for Over-the-Counter Loratadine; Alavert Shipments Will Begin Today.

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products Under Development for Nasopharyngitis (Common Cold), H2 2012

Products under Development for Nasopharyngitis (Common Cold) – Comparative Analysis, H2 2012

Number of Products under Development by Companies, H2 2012

Number of Products under Investigation by Universities/Institutes, H2 2012

Comparative Analysis by Late Stage Development, H2 2012

Comparative Analysis by Early Clinical Stage Development, H2 2012

Comparative Analysis by Pre-Clinical Stage Development, H2 2012

Products under Development by Companies, H2 2012

Products under Investigation by Universities/Institutes, H2 2012

Hydra Biosciences, Inc., H2 2012

Assessment by Monotherapy Products, H2 2012

Assessment by Combination Products, H2 2012

Assessment by Stage and Route of Administration, H2 2012

Assessment by Stage and Molecule Type, H2 2012

Nasopharyngitis (Common Cold) Therapeutics – Discontinued Products

Nasopharyngitis (Common Cold) Therapeutics – Dormant Products

List of Figures

Number of Products under Development for Nasopharyngitis (Common Cold), H2 2012

Products under Development for Nasopharyngitis (Common Cold) – Comparative Analysis, H2 2012

Products under Development by Companies, H2 2012

Products under Investigation by Universities/Institutes, H2 2012

Late Stage Products, H2 2012

Early Clinical Stage Products, H2 2012

Pre-Clinical Stage Products, H2 2012

Assessment by Monotherapy Products, H2 2012

Assessment by Combination Products, H2 2012

Assessment by Route of Administration, H2 2012

Assessment by Stage and Route of Administration, H2 2012

Assessment by Molecule Type, H2 2012

Assessment by Stage and Molecule Type, H2 2012

Abstract

• A snapshot of the global therapeutic scenario for Nasopharyngitis (Common Cold).
• A review of the Nasopharyngitis (Common Cold) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Nasopharyngitis (Common Cold) pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

• Identify and understand important and diverse types of therapeutics under development for Nasopharyngitis (Common Cold).
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) pipeline depth and focus of Nasopharyngitis (Common Cold) therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.